Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Richard Parker

Richard Parker is a transplant hepatologist at the Leeds Liver Unit and a senior lecturer at the University of Leeds in the United Kingdom. He received his medical degree in 2005 from the University of Bristol and completed his specialist hepatology training at the Birmingham Liver Transplant Unit. His post-graduate training included a PhD at the University of Birmingham, UK, focussing on inflammatory pathways in liver disease in steatotic liver disease, and a period as a visiting scientist at the NIH in Maryland, USA.

Dr Parker’s clinical and research interests are focussed on Alcohol related Liver Disease. He has led international collaborative groups to explore the natural history of ArLD and worked with multiple stakeholders to promote greater research activity in ArLD, especially in areas with high prevalence of disease but historically poor access to research. He leads the UK ArLD special interest group and is local principal investigator for a number of phase II and III clinical research studies.

Scroll to Top